skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Optimizing blood pressure control through the use of fixed combinations

Review

(2331) Views  (918) Full article downloads

Authors: Rainer Düsing

Published Date May 2010 Volume 2010:6 Pages 321 - 325
DOI: http://dx.doi.org/10.2147/VHRM.S9989

Rainer Düsing

Medizinische Klinik und Poliklinik 1, Bonn, Germany

Abstract: The majority of hypertensive patients need ≥2 antihypertensive agents to reach goal blood pressure. As an estimate, one-third of unselected hypertensive patients may be successfully treated with monotherapy, one-third may require 2 and the remaining one-third of patients will need ≥3 antihypertensive agents for effective blood pressure control. However, doctors are often hesitant to expand therapy in treated patients whose blood pressure is not lowered to goal (therapeutic inertia). Multiple-drug therapy in the majority of hypertensive patients may also represent one of several factors responsible for the low rates of adherence with chronic antihypertensive treatment. As a consequence, both US and European guidelines recommend single pill combinations to lower the number of pills needed in order to increase medication adherence and, possibly, reduce therapeutic inertia. For 2 drug combinations, the recently revised European (ESC/ESH) guidelines recommend the following options: diuretic plus either calcium channel blocker (CCB) or renin–angiotensin system (RAS) blocker (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker) or CCB plus RAS-blocker. In the absence of substantial evidence, neither JNC-7 (from 2003) nor the European guidelines from 2007 give any meaningful advice on triple combination treatment. It is therefore of interest that the 2009 reappraisal of the European guidelines gives preference to the combination of a RAS blocker and a CCB plus a diuretic. On the background of the substantial number of patients requiring ≥3 drugs for blood pressure control, the recent approval of a single-pill 3-drug combination composed in accordance with the above mentioned ESC/ESH recommendations should be appreciated.

Keywords: blood pressure, fixed-dose combinations, hypertension








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Can nocturnal hypertension predict cardiovascular risk?
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting
Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
Minimally invasive treatment of lumbar spinal stenosis with a novel interspinous spacer
Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-control study
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University